(Press-News.org) Patients with cystic fibrosis (CF) face difficulty breathing and a decline in lung function and are at risk of early death. CF is an inherited condition that results in thick mucus build-up, persistent infection and inflammation in the lungs.
Medical University of South Carolina (MUSC) researcher Patrick Flume, M.D., was lead author of a recent Journal of Cystic Fibrosis article reporting the findings of a trial of a two-drug combination for treating CF. The study demonstrated long-term safety and clinical benefit of the combination therapy. Flume is director of the MUSC Adult Cystic Fibrosis Center and co-director of the South Carolina Clinical & Translational Research (SCTR) Institute.
Patients 12 years and older who received the combination regimen of tezacaftor (TEZ) and ivacaftor (IVA) for four years did not experience any serious safety concerns and tolerated it well, suggesting its appropriateness for long-term use. These patients had previously participated in a 120-day trial of the same combination. The extension trial was conducted in SCTR’s Nexus Research Center.
Not only did patients tolerate the combination regimen over the course of the 96-week extension study, but they also maintained the improvements they had achieved in the earlier trial. The long-term safety and tolerability of this combination regimen is good news for patients with CF, many of whom will need to be on CF drug treatments for the rest of their lives.
Breakthrough therapies for cystic fibrosis
Although drugs to treat the symptoms of CF have been around for some time, the approval of IVA in 2012 marked a breakthrough in the treatment of the disease. It spawned a new class of CF drugs called modulators that addressed the underlying problem in CF rather than merely treating the sequelae of CF. When patients were treated with a combination of CF modulators targeting the structure and function of the protein, the effects were even more profound.
The trial reported here assessed the long-term efficacy and safety of treating patients with a combination of two CF modulators, TEZ and IVA (TEZ/IVA). While this trial was still being conducted, a three-part regimen composed of TEZ/IVA plus elexacaftor (Trikafta) was approved in 2019 and has since become standard of care.
“With TEZ/IVA, you see about a 2% to 3% increase in lung function in patients with CF, whereas with the triple, we see more like a 15% improvement in the lung function,” said Flume. “Patients are also less likely to require hospitalization. For example, before 2019, I would have anywhere from four to six people in the hospital on any given day. Now I have zero to one.”
These breakthrough therapies have dramatically improved the quality and length of patients’ lives.
“When I started in this business, the median survival was in the mid-20s, but now it's in the mid-50s,” said Flume. “I would tell you that if you had a child born with CF today, you should raise that child with the expectation of a long life. It shows how remarkable these modulators are and what their potential could be.”
How IVA and TEZ work
The protein, known as the cystic fibrosis transmembrane regulator, or CFTR, controls the movement of water in the lung tissues, allowing for thin, free-flowing mucus production. More than 90% of patients with CF have at least one F508del mutation in the CFTR gene. Those who carry two copies of this mutation, acquired from both parents, have a more severe form of CF. While some patients who inherit the mutation from only one parent may have less severe disease, others may still develop a severe form of CF.
IVA was the first small molecule that targeted the CFTR protein directly. It binds to the CFTR protein at the cell surface, holds the gate of the channel open and keeps the protein channel open longer to allow for the movement of water and decrease the thickness of mucus. However, this drug is appropriate only for those persons who have a mutation that produces protein at the cell surface, which does not occur in patients with F508del.
TEZ, referred to as a corrector, binds to the CFTR protein and helps the protein to maintain shape so that it can function better. This is important for those with F508del, as it can increase the quantity of protein at the cell surface, where it can now be acted upon by IVA.
What this study adds
Although clinicians recommend taking the three-drug combination regimen because of its increased effectiveness in improving lung function compared to TEZ/IVA, some patients cannot tolerate it and so must remain on the dual therapy. For example, one adverse effect of the triple combination is weight gain. In some cases, patients taking the triple combination have gained upward of 50 pounds. This study shows that patients who do not tolerate the triple combination can continue to benefit safely from the two-part regimen long term.
This study’s findings that TEZ/IVA is safe and well-tolerated over the long term also builds confidence that two of the three drugs in the standard-of-care therapy can be used safely over time. Again, this is important reassurance for patients who will likely take the drugs for the rest of their lives. Should safety issues arise, these data will be useful in pinpointing the problematic agent in the combination regimen.
The way forward
Clinician-researchers will continue to optimize combination therapy with CF modulators. Although refinements of these combination therapies continue to improve patient outcomes, Flume knows that can’t continue forever.
“Eventually, we're going to hit the ceiling – right? We can’t just keep going up and up and up, but we just don't know where that ceiling is,” he explained. “We had imagined we were there, and then ivacaftor blew that out of the water.”
Although modulators have improved the quality of life and increased the lifespan for many patients with CF, not all patients can tolerate them and not all have the F508del mutations that the CF modulators target. To help these subsets of patients, clinicians and scientists will continue to develop new CF therapies.
# # #
About MUSC
Founded in 1824 in Charleston, MUSC is the state’s only comprehensive academic health system, with a unique mission to preserve and optimize human life in South Carolina through education, research and patient care. Each year, MUSC educates more than 3,000 students in six colleges – Dental Medicine, Graduate Studies, Health Professions, Medicine, Nursing and Pharmacy – and trains more than 850 residents and fellows in its health system. MUSC brought in more than $297.8 million in research funds in fiscal year 2022, leading the state overall in research funding. For information on academic programs, visit musc.edu.
As the health care system of the Medical University of South Carolina, MUSC Health is dedicated to delivering the highest quality and safest patient care while educating and training generations of outstanding health care providers and leaders to serve the people of South Carolina and beyond. Patient care is provided at 14 hospitals with approximately 2,500 beds and five additional hospital locations in development, more than 350 telehealth sites and connectivity to patients’ homes, and nearly 750 care locations situated in all regions of South Carolina. In 2022, for the eighth consecutive year, U.S. News & World Report named MUSC Health the No. 1 hospital in South Carolina. To learn more about clinical patient services, visit muschealth.org.
MUSC and its affiliates have collective annual budgets of $5.1 billion. The nearly 25,000 MUSC team members include world-class faculty, physicians, specialty providers, scientists, students, affiliates and care team members who deliver groundbreaking education, research and patient care.
About the SCTR Institute
The South Carolina Clinical & Translational Research (SCTR) Institute is the catalyst for changing the culture of biomedical research, facilitating the sharing of resources and expertise and streamlining research-related processes to bring about large-scale change in clinical and translational research efforts in South Carolina. Our vision is to improve health outcomes and quality of life for the population through discoveries translated into evidence-based practice. To learn more, visit https://research.musc.edu/resources/sctr.
END
Breakthrough drug combination remains safe and effective in patients with cystic fibrosis after four years
: A multicenter study finds that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years while maintaining previously achieved clinical improvement.
2023-03-15
ELSE PRESS RELEASES FROM THIS DATE:
Remains of a modern glacier found near mars’ equator implies water ice possibly present at low latitudes on Mars even today
2023-03-15
March 15, 2023, Mountain View, California – In a groundbreaking announcement at the 54th Lunar and Planetary Science Conference held in The Woodlands, Texas, scientists revealed the discovery of a relict glacier near Mars' equator. Located in Eastern Noctis Labyrinthus at coordinates 7° 33' S, 93° 14' W, this finding is significant as it implies the presence of surface water ice on Mars in recent times, even near the equator. This discovery raises the possibility that ice may still exist at shallow depths in the ...
Associations between teacher and student mathematics, science, and literacy anxiety in fourth grade
2023-03-15
Educational Impact and Implications Statement
We investigated associations among teachers’ and students’ anxiety in mathematics, science, and literacy. We found that teachers’ anxiety in mathematics and science was associated with the mathematics and science anxiety of their low-SES students. Results highlight STEM content areas as contexts in which transmission of negative emotions between teachers and students may take place, as well as highlight the particular impacts these processes might have on students from underserved socioeconomic backgrounds.
The ...
Kerin Adelson, M.D., named MD Anderson Chief Quality and Value Officer
2023-03-15
HOUSTON ― The University of Texas MD Anderson Cancer Center today announced Kerin Adelson, M.D., as the institution’s chief quality and value officer. An accomplished clinician and researcher with extensive leadership experience in delivering high-quality and value-based cancer care, Adelson will begin her role March 20. She also will hold a faculty appointment in Breast Medical Oncology.
As chief quality and value officer, Adelson will partner with Chief Administrative Quality Officer José Rivera to lead MD Anderson’s medical practice quality improvement efforts and ...
For the first time, controlling the degree of twist in nanostructured particles
2023-03-15
Images
Micron-sized "bow ties," self-assembled from nanoparticles, form a variety of different curling shapes that can be precisely controlled, a research team led by the University of Michigan has shown.
The development opens the way for easily producing materials that interact with twisted light, providing new tools for machine vision and producing medicines.
While biology is full of twisted structures like DNA, known as chiral structures, the degree of twist is locked in—trying to change it breaks the structure. Now, researchers can engineer the degree of twist.
Such materials ...
Study unravels a cause of resistance to novel drug in patients with acute leukemia
2023-03-15
BOSTON – A new targeted drug has not only sparked remissions in patients with a common form of leukemia but also induced the cancer cells to reveal one of their schemes for resisting the drug, investigators at Dana-Farber Cancer Institute and other research centers report in a new pair of studies in the journal Nature.
One of the papers presents results of a clinical trial in which approximately 40% of patients with acute leukemia subtypes had a complete response – a disappearance of all signs of cancer – to treatment with the drug revumenib. The other paper uncovers a molecular countermove by which leukemia cells come to sidestep the drug and reassert their growth.
The ...
Making sense of scents: Deciphering our sense of smell
2023-03-15
Breaking a longstanding impasse in our understanding of olfaction, scientists at UC San Francisco (UCSF) have created the first molecular-level, 3D picture of how an odor molecule activates a human odorant receptor, a crucial step in deciphering the sense of smell.
The findings, appearing online March 15, 2023, in Nature, are poised to reignite interest in the science of smell with implications for fragrances, food science, and beyond. Odorant receptors - proteins that bind odor molecules on the surface of olfactory cells - make up half of the largest, most diverse family of receptors in our bodies; A deeper understanding of them paves the way for ...
Scientists discover key information about the function of mitochondria in cancer cells
2023-03-15
Scientists have long known that mitochondria, the "powerhouses" of cells, play a crucial role in the metabolism and energy production of cancer cells. However, until now, little was known about the relationship between the structural organization of mitochondrial networks and their functional bioenergetic activity at the level of whole tumors.
In a new study, published in Nature, researchers from the UCLA Jonsson Comprehensive Cancer Center used positron emission tomography (PET) in combination ...
Artificial Sweetener could dampen immune response to disease in mice
2023-03-15
Francis Crick Institute press release
Under strict embargo: 16:00hrs GMT Wednesday, March 15, 2023
Peer reviewed
Experimental study
Animals / Cells
Artificial Sweetener could dampen immune response to disease in mice
Scientists at the Francis Crick Institute have found that high consumption of a common artificial sweetener, sucralose, lowers activation of T-cells, an important component of the immune system, in mice.
If found to have similar effects in humans, one day it could be used therapeutically to help dampen T-cell responses. For example, in patients with autoimmune diseases who ...
New research shows recovering tropical forests offset just one quarter of carbon emissions from new tropical deforestation and forest degradation
2023-03-15
A pioneering global study has found deforestation and forests lost or damaged due to human and environmental change, such as fire and logging, are fast outstripping current rates of forest regrowth.
Tropical forests are vital ecosystems in the fight against both climate and ecological emergencies. The research, published today in Nature and led by the University of Bristol, highlights the carbon storage potential and the current limits of forest regrowth to addressing such crises.
The findings showed degraded forests recovering from human disturbances, and secondary forests regrowing ...
Targeting menin induces responses in acute leukemias with KMT2A rearrangements or NPM1 mutations
2023-03-15
Researchers from The University of Texas MD Anderson Cancer Center showed that inhibiting menin with revumenib, previously known as SNDX-5613, yielded encouraging responses for advanced acute leukemias with KMT2A rearrangements or mutant NPM1. Findings from the Phase I AUGMENT-101 trial were published today in Nature.
The overall response rate among 60 patients was 53%, and the rate of complete remission or complete remission with partial hematologic recovery was 30%, with 78% of patients achieving clearance of measurable residual disease. Responses were seen across multiple dose ...
LAST 30 PRESS RELEASES:
A new discovery about the source of the vast energy in cosmic rays
Cancer ‘fingerprint’ can improve early detection
Rethinking the brain pacemaker: How better materials can improve signals
Allostatic load, educational attainment, and risk of cancer mortality among us men
Flaw in computer memory leads to global security fixes
Race, ethnicity, and sleep in us children
Geriatric surgery verification program can improve outcomes for older cancer patients in community hospitals
Pew funds 8 teams to conduct collaborative biomedical research
Finding innovative ways to address kidney cancer leads to DoD grant
Americans are uninformed about and undervaccinated for HPV
KTU scientists developed a nanolaser: silver nanocubes enable light generation
Insilico Medicine nominates orally available pre-clinical candidate targeting NLRP3 to treat inflammation and central nervous system diseases
PLOS receives $3.3 million grant to support Open Access publishing & business model transformation
HBx facilitates drug resistance in hepatocellular carcinoma via CD133-regulated self-renewal of liver cancer stem cells
ASN congratulates members for their role in the development of the Scientific Report of the 2025 Dietary Guidelines Advisory Committee
Late-stage breast cancer diagnosis on the rise in US
Brain volume changes seen in opioid users
Ultra-processed foods may drive colorectal cancer risk, USF-TGH study finds
Two Case Western Reserve University faculty members honored as Fellows of the National Academy of Inventors
How this cancer drug could make radiation a slam dunk therapy
National TRAP Program funds large-scale cleanup of discarded fishing gear
Using ‘biological age’ to predict early colorectal cancer risk
National Academy of Inventors announces Class of 2024 Fellows
SwRI showcases capabilities, evaluates novel fire-safety method with customized test
Caring for the emotional and spiritual needs of family members of ICU patients
Navigating crises: The financial adaptations of NGOs during the COVID-19 pandemic
Early life exposure to toxic chemicals may cause behavioral, psychological problems
AI predicts Earth’s peak warming
Risk of coronary artery disease in patients with liver cirrhosis: A systematic review and meta-analysis
Wild birds’ gut microbiome linked with its ornamentation and body condition
[Press-News.org] Breakthrough drug combination remains safe and effective in patients with cystic fibrosis after four years: A multicenter study finds that patients with cystic fibrosis can safely take a dual combination of CF modulator drugs for four years while maintaining previously achieved clinical improvement.